Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
Hyperlipidemic patients with coronary heart disease were treated with atorvastatin, and its effects on hemostatic and inflammatory parameters were assessed. After 3 months of therapy, the plasma levels of plasminogen activator inhibitor, prothrombin fragment 1+2, highly sensitive C-reactive protein, von Willebrand factor, and fibrinogen were significantly reduced; no significant reductions were observed in lipoprotein(a) and tissue plasminogen activator antigen levels.
Tekin
Abdullah
A
Department of Cardiology, Faculty of Medicine, Başkent University, Adana, Turkey.
Tekin
Göknur
G
Güzelsoy
Deniz
D
Kaya
Ayşem
A
Gürel
Ciğdem Vural
CV
Yiğit
Zerrin
Z
Ulutin
Turgut
T
D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000032:analysis; D015897:Comorbidity; D017023:Coronary Angiography; D003327:Coronary Disease / Q000453:epidemiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D017270:Lipoprotein(a) / Q000097:blood; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011446:Prospective Studies; D011516:Prothrombin; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000097:blood
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D017270:Lipoprotein(a); D010446:Peptide Fragments; D011758:Pyrroles; C045879:prothrombin fragment 1.2; D011516:Prothrombin; D002097:C-Reactive Protein; D000069059:Atorvastatin; D010959:Tissue Plasminogen Activator